Davenport & CO LLC Bristol Myers Squibb CO Transaction History

Davenport & CO LLC

$16 Billion
Q2 2024

A detailed history of Davenport & CO LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Davenport & CO LLC holds 2,296,146 shares of BMY stock, worth $123 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

2,296,146

Previous 2,385,483 3.75%

Holding current value

$123 Million

Previous $129 Million 26.29%

% of portfolio

0.6%

Previous 0.82%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$40.25 - $52.99 $3.6 Million - $4.73 Million	-89,337 Reduced 3.75%	2,296,146 $95.4 Million
Q1 2024 May 03, 2024	BUY	$47.98 - $54.4 $10.4 Million - $11.7 Million	215,717 Added 9.94%	2,385,483 $129 Million
Q4 2023 Jan 23, 2024	BUY	$48.48 - $57.85 $11.4 Million - $13.5 Million	234,123 Added 12.1%	2,169,766 $111 Million
Q3 2023 Oct 17, 2023	BUY	$57.89 - $64.73 $38.5 Million - $43 Million	664,626 Added 52.29%	1,935,643 $112 Million
Q2 2023 Jul 20, 2023	BUY	$63.71 - $70.74 $64 Million - $71 Million	1,004,088 Added 376.16%	1,271,017 $81.3 Million
Q1 2023 Apr 27, 2023	SELL	$65.71 - $74.53 $403,787 - $457,986	-6,145 Reduced 2.25%	266,929 $18.5 Million
Q4 2022 Jan 20, 2023	SELL	$68.48 - $81.09 $1.15 Million - $1.36 Million	-16,790 Reduced 5.79%	273,074 $0
Q3 2022 Oct 11, 2022	SELL	$0.13 - $76.84 $4,543 - $2.69 Million	-34,952 Reduced 10.76%	289,864 $20.6 Million
Q2 2022 Jul 18, 2022	SELL	$72.62 - $79.98 $1.49 Million - $1.64 Million	-20,515 Reduced 5.94%	324,816 $25 Million
Q1 2022 May 02, 2022	SELL	$61.48 - $73.72 $2 Million - $2.39 Million	-32,451 Reduced 8.59%	345,331 $25.2 Million
Q4 2021 Feb 10, 2022	SELL	$53.63 - $62.52 $59.9 Million - $69.8 Million	-1,116,601 Reduced 74.72%	377,782 $23.6 Million
Q3 2021 Oct 14, 2021	BUY	$59.17 - $69.31 $3.64 Million - $4.26 Million	61,521 Added 4.29%	1,494,383 $88.4 Million
Q2 2021 Jul 28, 2021	BUY	$61.91 - $67.42 $2.2 Million - $2.4 Million	35,560 Added 2.54%	1,432,862 $95.7 Million
Q1 2021 Apr 28, 2021	SELL	$59.34 - $66.74 $580,463 - $652,850	-9,782 Reduced 0.7%	1,397,302 $88.2 Million
Q4 2020 Jan 13, 2021	SELL	$57.74 - $65.43 $427,333 - $484,247	-7,401 Reduced 0.52%	1,407,084 $87.3 Million
Q3 2020 Oct 15, 2020	SELL	$57.43 - $63.64 $1.96 Million - $2.18 Million	-34,183 Reduced 2.36%	1,414,485 $85.3 Million
Q2 2020 Jul 28, 2020	SELL	$54.82 - $64.09 $746,100 - $872,264	-13,610 Reduced 0.93%	1,448,668 $85.2 Million
Q1 2020 May 05, 2020	SELL	$46.4 - $67.43 $24.9 Million - $36.2 Million	-536,718 Reduced 26.85%	1,462,278 $81.5 Million
Q4 2019 Jan 22, 2020	BUY	$49.21 - $64.19 $3.22 Million - $4.2 Million	65,483 Added 3.39%	1,998,996 $128 Million
Q3 2019 Oct 16, 2019	SELL	$42.77 - $50.71 $843,595 - $1 Million	-19,724 Reduced 1.01%	1,933,513 $89.7 Million
Q2 2019 Jul 10, 2019	BUY	$44.62 - $49.34 $21.4 Million - $23.7 Million	479,370 Added 32.52%	1,953,237 $88.6 Million
Q1 2019 Apr 17, 2019	BUY	$45.12 - $53.8 $4.57 Million - $5.45 Million	101,268 Added 7.38%	1,473,867 $70.3 Million
Q4 2018 Jan 28, 2019	SELL	$48.76 - $63.23 $476,238 - $617,567	-9,767 Reduced 0.71%	1,372,599 $71.3 Million
Q3 2018 Oct 11, 2018	BUY	$55.19 - $62.25 $694,510 - $783,354	12,584 Added 0.92%	1,382,366 $85.8 Million
Q2 2018 Jul 09, 2018	BUY	$50.53 - $62.98 $10.1 Million - $12.6 Million	200,804 Added 17.18%	1,369,782 $75.8 Million
Q1 2018 Apr 04, 2018	SELL	$59.92 - $68.98 $1.1 Million - $1.26 Million	-18,304 Reduced 1.54%	1,168,978 $73.9 Billion
Q4 2017 Jan 17, 2018	SELL	$59.94 - $65.35 $1.73 Million - $1.89 Million	-28,943 Reduced 2.38%	1,187,282 $72.8 Billion
Q3 2017 Oct 12, 2017	BUY	$55.23 - $63.74 $67.2 Million - $77.5 Million	1,216,225	1,216,225 $77.5 Billion

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $114B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.

Account